Fundamental Analysis of BICYCLE THERAPEUTICS PLC-ADR(NASDAQ:BCYC) stock

Fundamental Rating

Overall BCYC gets a fundamental rating of 3 out of 10. We evaluated BCYC against 588 industry peers in the Biotechnology industry. The financial health of BCYC is average, but there are quite some concerns on its profitability. BCYC is valued quite expensively, but it does show have an excellent growth rating.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year BCYC has reported negative net income.

BCYC had a negative operating cash flow in the past year.

BCYC had negative earnings in each of the past 5 years.

BCYC had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -30.35%, BCYC is in the better half of the industry, outperforming 72.87% of the companies in the same industry.

Looking at the Return On Equity, with a value of -48.70%, BCYC is in the better half of the industry, outperforming 69.11% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-30.35%
ROE	-48.7%
ROIC	N/A

ROA(3y)-23.91%

ROA(5y)-26.23%

ROE(3y)-36.54%

ROE(5y)-39.18%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

BCYC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

BCYC does not have a ROIC to compare to the WACC, probably because it is not profitable.

BCYC has more shares outstanding than it did 1 year ago.

The number of shares outstanding for BCYC has been increased compared to 5 years ago.

The debt/assets ratio for BCYC has been reduced compared to a year ago.

2.2 Solvency

BCYC has an Altman-Z score of 1.28. This is a bad value and indicates that BCYC is not financially healthy and even has some risk of bankruptcy.

BCYC has a better Altman-Z score (1.28) than 66.04% of its industry peers.

BCYC has a Debt/Equity ratio of 0.08. This is a healthy value indicating a solid balance between debt and equity.

BCYC's Debt to Equity ratio of 0.08 is on the low side compared to the rest of the industry. BCYC is outperformed by 63.14% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.08
Debt/FCF	N/A
Altman-Z	1.28

ROIC/WACCN/A

WACC8.62%

2.3 Liquidity

BCYC has a Current Ratio of 8.08. This indicates that BCYC is financially healthy and has no problem in meeting its short term obligations.

BCYC's Current ratio of 8.08 is fine compared to the rest of the industry. BCYC outperforms 73.21% of its industry peers.

A Quick Ratio of 8.08 indicates that BCYC has no problem at all paying its short term obligations.

BCYC has a better Quick ratio (8.08) than 73.38% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	8.08
Quick Ratio	8.08

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for BCYC have decreased strongly by -35.00% in the last year.

The Revenue has grown by 86.46% in the past year. This is a very strong growth!

BCYC shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 30.45% yearly.

EPS 1Y (TTM)-35%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q-14.85%

Revenue 1Y (TTM)86.46%

Revenue growth 3Y37.44%

Revenue growth 5Y30.45%

Revenue growth Q2Q67.12%

3.2 Future

BCYC is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.32% yearly.

The Revenue is expected to grow by 63.22% on average over the next years. This is a very strong growth

EPS Next Y-3.09%

EPS Next 2Y-4.72%

EPS Next 3Y-2.89%

EPS Next 5Y12.32%

Revenue Next Year-9.49%

Revenue Next 2Y-11.69%

Revenue Next 3Y11.99%

Revenue Next 5Y63.22%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

BCYC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year BCYC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

BCYC's earnings are expected to decrease with -2.89% in the coming years. This may justify a cheaper valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-4.72%

EPS Next 3Y-2.89%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for BCYC!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

BICYCLE THERAPEUTICS PLC-ADR

NASDAQ:BCYC (5/3/2024, 7:00:01 PM)

After market: 24.58 0 (0%)

24.58

-0.11 (-0.45%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap933.24M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-30.35%
ROE	-48.7%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.05

Health

		Industry Rank	Sector Rank
Debt/Equity	0.08
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	8.08
Quick Ratio	8.08
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)-35%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y-3.09%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)86.46%

Revenue growth 3Y37.44%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

BICYCLE THERAPEUTICS PLC-ADR (BCYC)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens